Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice.
10.4093/jkd.2017.18.3.135
- Author:
Nam Hoon KIM
1
;
Sin Gon KIM
Author Information
1. Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. k50367@korea.ac.kr
- Publication Type:Editorial
- Keywords:
Diabetes mellitus;
type 2;
Dipeptidyl-peptidase IV inhibitors;
Safety;
Sodium glucose cotransporter 2 inhibitor
- MeSH:
Diabetes Mellitus;
Dipeptidyl-Peptidase IV Inhibitors;
Glucose*;
Sodium*
- From:Journal of Korean Diabetes
2017;18(3):135-140
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are newer classes of glucose-lowering agents that are currently widely used in clinical practice. Their glycemic efficacy and cardiovascular safety have been well proven, and recent large clinical trials even have shown cardiovascular benefits of SGLT2 inhibitors. However, data regarding drug-related long-term safety remain inconclusive. Recently, several safety issues related to DPP-4 inhibitors and SGLT2 inhibitors have been raised by cardiovascular outcome trials or post-marketing pharmacoepidemiological studies. In this review, we summarize emerging safety issues regarding the use of DPP-4 inhibitors and SGLT2 inhibitors in type 2 diabetes and suggest how to interpret and apply these results to clinical practice.
